Rep. Lisa C. McClain Sells Becton, Dickinson and Company (NYSE:BDX) Stock

Key Points

• Representative Lisa C. McClain sold shares of Becton, Dickinson and Company (NYSE: BDX) valued between $1,001 and $15,000 on June 24th, as disclosed in a filing on August 13th.
• Becton, Dickinson and Company reported a quarterly EPS of $3.68, surpassing expectations, and achieved revenue growth of 10.4% compared to the previous year.
• The company declared a quarterly dividend of $1.04 per share, with the payment scheduled for September 30th, reflecting an annualized yield of 2.1%.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Becton, Dickinson and Company NYSE: BDX. In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Becton, Dickinson and Company stock on June 24th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Becton, Dickinson and Company Stock Down 0.6%

NYSE BDX traded down $1.1830 on Thursday, reaching $198.0170. The company had a trading volume of 253,287 shares, compared to its average volume of 2,649,885. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm has a 50-day moving average of $179.66 and a 200-day moving average of $196.25. The firm has a market capitalization of $56.76 billion, a PE ratio of 35.61, a P/E/G ratio of 1.48 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. During the same period in the previous year, the company posted $3.50 earnings per share. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company's payout ratio is 74.82%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president owned 4,575 shares of the company's stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Claire Fraser sold 863 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the transaction, the director directly owned 23,143 shares of the company's stock, valued at $4,450,398.90. This trade represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,214 shares of company stock worth $579,206. Insiders own 0.36% of the company's stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Becton, Dickinson and Company by 15.4% during the 2nd quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier's stock worth $5,565,182,000 after purchasing an additional 4,305,947 shares during the period. Norges Bank bought a new position in Becton, Dickinson and Company during the 2nd quarter worth $653,377,000. First Eagle Investment Management LLC increased its position in Becton, Dickinson and Company by 59.2% in the second quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier's stock worth $1,513,421,000 after buying an additional 3,268,478 shares during the period. T. Rowe Price Investment Management Inc. increased its position in Becton, Dickinson and Company by 36.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock worth $2,751,187,000 after buying an additional 3,219,317 shares during the period. Finally, GQG Partners LLC bought a new stake in Becton, Dickinson and Company in the first quarter valued at $689,833,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on BDX shares. Piper Sandler reaffirmed a "neutral" rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Raymond James Financial lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Barclays cut their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Stifel Nicolaus decreased their price target on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Citigroup cut shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their price target for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of "Hold" and an average target price of $211.44.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.